It is rare case and real tough one. A clue : concentrate inside the pericardial space. (36, year old man , asymptomatic)
Know the diagnosis
Source and reference & Courtesy
Comment : Most curious , who stopped it from entering LV ?
Archive for the ‘Uncategorized’ Category
An Echo quiz
Posted in Uncategorized, tagged bullet injuries of heart, echocardiography, gun shot injury of heart, miracles in clinical cardiology, pericardial disease, rare cases in cardiology, rare foreign body in heart on January 27, 2026|
LV mural thrombus following STEMI : Welcome on board NOACs , they are safe…but, please don’t ask about efficacy !
Posted in Uncategorized, tagged doac for lv mural thrombus, doac vs oac, efficacy of doac in lv thrombus, rivaroxaban, warfarin vs doacs on January 21, 2026|
Does DOACs trying to push over warfarin in post STEMI LV mural thrombus ?
Yes , it seems so. Old must give way for new, even if it is gold. We need to go with the trend. Only thing, we need to prove is, whether the new ones are safe . Need not bother much about efficacy. Some one, will somehow, prove the new ones , non-Inferior to the best available drug as on date.
Every experienced cardiologist would know, Warfarin is many-fold more effective. But, still NOACs are coming in a big way. With the help of big trials, NOACs will ultimately replace the much more dangerous, bleed-prone Warfarin. One more reason we might embrace the inferior drug is the clinical inertia for vigilant INR monitoring.
What does the evidence say ?
Read : Ref 2
The future of medicine will be fight between quality & ( Intention ) of evidence and experience
Caution : Personal opinion
It would be science at its best, when a less potent drug, that requires zero monitoring, will replace a more potent and established OAC. It doesn’t require brilliant brains, to realize a drug which has less bleeding risk, is going to be less effective in getting rid of thrombus as well. (The trial in Ref 2 proved otherwise)
Only issue with warfarin is, we need to be a little more careful. Fortunately, its usage in LV mural thrombi is not likely to be permanent. (as in prosthetic valve)
Reference
AHA comprehensive review on LV thrombus management
A new pre specified -meta-analysis (I don’t know what it means) from a popular Journal EuroIntervention shows a strong evidence in favor for DOACS
In the above study, Warfarin trails behind Rivaroxaban by a huge 20% margin in it’s ability to successfully remove LV thrombus.
TThere is a surprise in the conclusion : Why do the authors, hesitate to commit DOACS are superior? Something to think about.
Science can wait … not the suffering patients!
Posted in Uncategorized, tagged best medical quotes, bmj, hippocrates, jama dr s venkatesan sangareddi, lancet, medical ethics, nejm, osler willam, pateint care vs science, practical bio ethcis, primum non nocere, science and ethics on January 14, 2026|
Looks like, this could turn out, to be the greatest Innovation in Cardiology : Percutaneous Aorta-Coronary bypass
Posted in Uncategorized, tagged BASILICA, CATHEDRAL, innovations in cardiology, NEO CORONARY OSTIUM, PERCUTANEOUS cabg, TACKLING CORONARY OBSTRUCTION AFTER TAVI, TAVR, UNICORN, VECTOR on January 14, 2026|
Innovation and Interventional cardiology are like Inseparable conjoined kids. When a mind blowing idea shakes hands with unprecedented technology, supported by an accommodating industry, such breakthroughs happen.
First In human : Creation of neo-coronary ostium & by pass stent to LAD
Here is an ultimate intervention, called the VECTOR procedure, that creates a tunneling pathway outside the regular anatomical pathways, like laying a road or metro tunnel under a mountain or river. (Ref 1 Circulation Cardiovascular Intervention 2026)
Combining the expertise of the retrograde approach of CTO and covered stent technology, a neo coronary ostium and an artificial artery is created that connects the ascending aorta and LAD, burrowing through the epicardium, myocardium, and pericardial plane.
VECTOR procedure : Ventriculo-coronary transcatheter outward navigation and reentry (VECTOR)
1.Who is the patient ?
A very high risk post TAVR, who had a blocked his left coronary ostium. VECTOR was attempted in lieu of CABG, which probably he was not eligible.
2.Where it was done ?
I think it was done at Emory , the same place Andreas Gruentzig, show cased his magnum opus.
(It is a combined innovation from four institutes Structural Heart and Valve Center, Emory University Hospital, Atlanta, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, St Francis Hospital and Heart Center, NY, MedStar Washington Hospital Center and Georgetown University, Washington, DC0
3.What are possible percutaneous solutions to prevent coronary ostial obstruction ?
1.BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction)
2.UNICORN (Undermining Iatrogenic Coronary Obstruction With Radiofrequency Needle)
3.CATHEDRAL (CATHeter Electrosurgical Debulking and RemovAL)
The VECTOR procedure , first in human human was attempted
4.Now, what are challenges ? Will such procedure stand the test of time ?
The key question is, (apart from complexities and complications of the VECTOR procedure) how the covered stent will seal the peri-anastomotic site both in the aorta and coronary end?
5.Is this procedure possible in a non-TAVR situation in complex ostial and left main disease?
Time will tell
6.A venous and hepatic analogy
I don’t know this comparison is correct. VECTOR procedure has some similarities with the TIPS procedure done as percutaneous portal vein to IVC connection through the hepatic tissue planes (Vignali C, TIPS with expanded polytetrafluoroethylene-covered stent: results of an Italian multicenter study. AJR Am J Roentgenol. 2005 )
Final message
If we can, somehow make the procedure simple with smaller hardware, circumventing VECTOR will be an ultimate victory for mankind and sure to stand tall in the pinnacles of glory.
However , when adopting new technologies “Always be ready, to sacrifice science , if you think it would interfere with patient well being”.
Reference
Cardio renal syndrome : Can’t Ignore ,Right ventricle’s secret agenda
Posted in Uncategorized, tagged cardio renal syndrome, heaptic and reanl congestion, ivc hypertension in cardio renal syndrome, renal vensous hypertension, Role of right ventricle in cardio renal syndrome, rv dysfunction in cardio renal syndrome on January 11, 2026|
Cardio-renal syndrome (CRS) , in reality seems to be , a vague clinical entity, defined and classified into 5 types essentially for our convenience and simplicity. This classification do not contribute to any pathophysiological insights . The fact of the matter is, every patient with heart failure (both acute and chronic) has some amount of renal compromise & vice versa. The link between LV failure and renal compromise is more discussed and documented in the literature than the influence of the right ventricle.
Now evidence is emerging, like hepatic congestion , renal venous congestion also play an important role in compromising renal function. Traditionally, we aim to increase the GFR, by improving renal blood flow, but the real problem may lie in clearing the exit paths of the renal venous system.
A mini review on the topic
Right ventricular (RV) dysfunction in chronic heart failure (HF) contributes to renal dysfunction beyond reduced forward cardiac output, primarily through backward venous congestion elevating inferior vena cava (IVC) pressure and renal venous hypertension. This congestion transmits high central venous pressure (CVP) to renal veins, increasing interstitial pressure, compressing tubules, and impairing glomerular filtration rate (GFR) independent of arterial underperfusion. Studies confirm IVC dilatation and CVP >8 mmHg correlate with worsened renal function, reversible by decongestion.
Venous Congestion Mechanisms
Elevated RV filling pressures cause systemic congestion, reducing trans-renal perfusion pressure (mean arterial pressure minus CVP) and promoting renal parenchymal hypoxia. Animal models show renal venous pressure elevation decreases urine output and GFR more than equivalent arterial hypotension, via tubulo-glomerular feedback disruption and renin-angiotensin-aldosterone system activation. Human data from acute decompensated HF link high RAP/CVP to serum creatinine rise, with decongestion improving GFR in RV failure.
Reflex and Neurohormonal Pathways
RV-driven congestion activates intrarenal mechanoreceptors, triggering sympathetic vasoconstriction and hepatorenal/splenorenal reflexes that exacerbate sodium retention. Splanchnic pooling limits venous capacitance, amplifying intra-abdominal pressure and gut-derived inflammation (e.g., LPS translocation), fostering a proinflammatory milieu worsening cardiorenal interactions. Ventricular interdependence from RV dilation further impairs left ventricular output, compounding renal hypoperfusion.
Clinical Evidence from AHA Context
The AHA Scientific Statement on Cardiorenal Syndrome emphasizes venous hypertension over hypoperfusion in CRS type1 and 2 stressing the importance of ESCAPE/DOSE trial results on diuretic-guided decongestion.
Clinical Implication
Major implication is the role of optimizing diuretic dose in HF, which can reduce renal venous congestion . Treatment strategies aiming to improve pulmonary hypertension and RV function seems important as well.
Final message
If we need to manage cardio-renal syndrome effectively, we need to pull both Cardiologists and Nephrologists to sit in a combined consultation (a difficult proposition in current times), and review patient data, optimizing the strengths and weaknesses of all pillars of heart failure drugs, and (more importantly) fine-tuning the important fifth pillar, the diuretics*.
*For some reason, the literature and cardiology community refuses to admit a blatant truth : Diuretics are life-saving in heart failure.
Further reading
How to treat Congestive Cardio-Renal failure ?
How do mitral valve balance its Tethering and Closing Forces ?
Posted in Uncategorized, tagged coapt study, eccentric cs concentric mr, jacc, lancet, lub dub, macr, Mechanism of mitral regurgitation, mitra clip, mitral annulus, nejm, role of stethoscope in current era, scai, TAVR, teer, tethering cs closing forces in mitral valve on January 3, 2026|
Preamble : The Lubs & Dubs
The lubs and dubs, along with some added sounds are the only language, the heart can speak in health and distress. It’s a worrying story altogether, gradually many of us are becoming “cardiac illiterates” as we struggle to read , its gentle communication. it is not our fault. Stethoscopes are reduced to become a social marker of being a doctor. We may excuse ourselves, even if we can’t differentiate a systolic from diastolic murmur, after all, hand held echo machines, instantly tell the diagnosis.
( After reading this article, fellows are expected to understand why the first heart sound in MR (ie the lubs,) are mostly soft, some times normal or even loud in certain conditions)
Now, let us go to the mitral valve dynamics
How many of us are aware, there is a big science of physics and biology operating when the mitral valve perfectly closes at the level of the annulus, with each systole , balancing different sets of known and unknown forces.
In this article, we will see how these two sets of forces mitral valve tethering and closing forces balance out each other to seal the mitral valve and what happens when the forces begin to fight each other.
Balance of Tethering and Closing Forces in Mitral Valve Coaptation
The mitral valve (MV) coaptation refers to the edge-to-edge apposition of the anterior and posterior leaflets during systole, ensuring a competent seal to prevent regurgitation. This process is governed by a delicate balance between tethering forces (which restrain leaflet motion to prevent prolapse into the left atrium) and closing forces (which approximate the leaflets for sealing).
- Tethering forces: These are primarily transmitted through the chordae tendineae from the papillary muscles (PMs) to the leaflet free edges and bellies, pulling the leaflets apically and laterally toward the left ventricular (LV) apex. They arise from:
- Closing forces: These are driven by the transmitral pressure gradient during systole, where rising LV pressure (generated by LV contraction) exceeds left atrial (LA) pressure, pushing the leaflets together. The force is proportional to the LV dP/dt (rate of pressure rise) and peaks in midsystole.
- Balancing mechanism: Coaptation occurs when closing forces overcome tethering, enabling leaflets to meet with sufficient overlap (coaptation length >8 mm typically). Imbalance favors regurgitation: excessive tethering (e.g., from PM displacement) causes apical tenting and incomplete closure; insufficient closing (e.g., low LV contractility) fails to seal the orifice. In health, the forces are synchronized with systole, with closing forces dominating midsystole to minimize the effective regurgitant orifice area (EROA).
Paradoxes in the Balancing Mechanism
MV mechanics exhibit several counterintuitive paradoxes, where adaptive or dysfunctional responses lead to outcomes opposite to expectations. These highlight the interplay of geometry, contractility, and force transmission:
- Paradoxical systolic PM elongation: Normally, PMs shorten during systole (1 cm) to offset annular descent and maintain annulopapillary balance. Post-myocardial infarction (MI), scarred or ischemic PMs paradoxically elongate driven by transmitral pressure tension. This decreases annulopapillary distance, attenuates tethering, and reduces MR severity—contrary to the intuition that PM weakness worsens regurgitation. However, extreme elongation risks leaflet prolapse, flipping the paradox to increased MR.
- PM dysfunction attenuating ischemic MR: In isolated dysfunction, reduced PM contraction intuitively increases slack chordae and prolapse risk. Yet, in localized basal inferior LV remodeling, PM dysfunction (measured as reduced longitudinal systolic strain) inversely correlates with MR fraction attenuating MR by limiting excessive tethering. This holds only with certain level of remodeling . Gross and asymmetrical remodeling can exaggerate tethering and increase the MR.
- Dynamic EROA reduction despite peak driving pressure: MR often peaks early systole (when closing forces are low and tethering dominates) but paradoxically decreases midsystole, even as LV pressure (driving force) maximizes. This occurs because rising closing forces (transmitral gradient) overcome tethering, shrinking the orifice mimicking reduced regurgitation when it should worsen.Thgis mechansim can some times seen when MR jet is bi-fid in doppler tracing.
- Imbalanced chordal forces causing focal prolapse: In acute ischemic MR (e.g., posterior wall ischemia), tethering redistributes unevenly: tension drops in ischemic-side chordae but rises on the nonischemic side causing focal tenting and relative prolapse on the ischemic commissure. This creates an eccentric jet despite global LV contraction.
This article clearly tells us that the forces acting on the mitral valve apparatus are so complex. The conceptual model of tethering and closing forces may be oversimplified. There are variable interactions between them. More importantly, the atrial forces also influence and intrude into these forces. Realize that MV competence is not just about force magnitude but their vectorial distribution and timing, often amplified by LV geometry changes.
Final message
As cardiologists and surgeons, we must realize the fact, how important it is to analyze both anatomy and the physiological impact when we rush to clip, cut, or repair it with annuloplasty and subvalvular interventions.
*Sometimes, it might even be tempting to do mitral valve replacement, even when it is not indicated, because we need not bother about all these dizzy mechanics and physics of MR jet forces.
A “New Year” & An “Old Wish”
Posted in Uncategorized on January 1, 2026|
As we enter, another customary happy “New year” , a lingering “Old wish” remains largely unfulfilled. Let us try to return, to our forgotten home space, called patient’s bed side . Shall get Immersed in history taking , Intuitive clinical examination, and master the art of listening to our patient’s heart with our own ears. Investigations can wait unless it is a dire emergency.
Too often today, we bypass these foundations, relying blindly on Images, echocardiograms, angiograms, a deluge of scans, , multi-modality algorithms ,AI predictions. We have also become greedy servants to technology commerce , and increasingly intoxicating science as well. Let us not insist on investigations , driven by peer pressures or pride, in the process losing common sense in a flood of data.
Let us reclaim the intellect, that taught us listening and understanding to the patients symptoms (with kindness) is the highest form of Investigation .
Coming to scientific research, grow courage to question, debate , that ultimately would simplify complex problems .
Finally, seek the truth, which often hides behind the distorted evidence base and obsessive compulsive protocols.
Welcome to new year 2026
Greeting & regards from Chennai.
Dr. S.Venkatesan
Permanent Aortic filter : A pre-clinical proposal for PAA-PMF, device for long term stroke prevention
Posted in Uncategorized, tagged acc, aortic filter, circualtion research, embol x, esc, innovations in cardiology, ivc filter, laaa occluder, lancet jacc interventions, nejm, PAA-PMF, permanent aortic filter, scai, sentinel device, stroke prevention, TAVR, triguard on December 24, 2025|
“Every Interventional Cardiologist, realistically, need to be a preventive neurologist too!”
The concept a permanent ascending aortic porous membrane filter (PAA-PMF) is an extrapolation of the idea of mechanical thrombus capture, as proven by IVC filters for venous embolism prevention . Also we do have and temporary intra-aortic filters like Sentinel , Embol-X for arterial particulate capture.
Device Concept
The PAA-PMF would feature a self-expanding nitinol frame, with a fully porous head end. The device can be heparin-coated polyester or polyurethane mesh membrane, deployable via 12-14 Fr femoral sheath, similar to IVC filter designs but should be optimized for aortic pressures. Suggested pore size of 100-125 μm targets >100 μm emboli, akin to Embol-X filtration efficacy in capturing 95% of particulates (atheroma, fibrin) during aortic declamping. The essential requirement is that the porous membrane should not create an impedance gradient. How feasible it is, to be tested. Conical shape, the radial force will ensure good ascending aortic wall apposition.
Device location site
Site of placement is critical. Proximal ascending aorta, 2-3 cm distal to sinotubular junction/proximal to brachiocephalic trunk, as in Embol-X for maximal cardiac/aortic debris interception without coronary/arch compromis
Potential indications
(Only in patients with very high risk of cardioembolic stroke)
1.Chronic stroke reduction in patients with MVR/AVR/TAVR/MAVR
2.High-risk mobile LV mural thrombus
3.Chronic AF with visible and invisible clots in LA
4..High-risk procoagulant conditions with recurrent embolism
Definite Risks
*Occlusion and hemodynamic compromise is the most crucial issue. However, when compared to the incidence IVC filter clogging, the high pressure aortic flow is likely to self-wash the device (as happens in a prosthetic aortic valve)
Trapped emboli may enter into coronary circulation is a possibility. Putting a filter at ascending aorta precludes left heart catheterization.
*Migration , Hemolysis are other expected complications.
Intense anticoagulation would be required to prevent occlusion of the filte . (Still, stopping it temporarily doe not not increase the risk of stroke)
Final message : Is it Worth for a Preclinical trial ?
We do have temporary aortic filters. The concept of permanent or semi-permanent filters is largely theoretical, with potential risks being more than benefits. The device can take care of only cardio-aortic embolic stroke.
However, considering so many complex, risky intracardiac and intravascular devices being tested on a daily basis, it is not a big deal for the current generation of interventional cardiologists to try this.
More than our interventional appetite, we really need a device that prevents stroke in a permanent fashion. It is definitely worthy to do initial studies in a porcine model. Would be glad , if Edwards, Abbot or Medtronic and other new Innovators respond to this.
References
- Shammas NW, et al. Intra-Aortic Filtration: Capturing Particulate Emboli during Cardiopulmonary Bypass. NIH. 2004. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1351822/
- Shammas NW, et al. Embol-X Intra-Aortic Filtration System: Capturing Particulate Emboli in the Cardiac Surgery Patient. NIH. 2004. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4682540/
- PCI Mag. Revolutionary Anti-Thrombogenic Coating for Stents Promises Safer, Faster Healing. 2024. Available from: https://www.pcimag.com/articles/112641-revolutionary-anti-thrombogenic-coating-for-stents-promises-safer-faster-healing
- Kaufman JA, et al. Radiologists’ Field Guide to Retrievable and Convertible Inferior Vena Cava Filters. AJR. 2019. Available from: https://ajronline.org/doi/10.2214/AJR.19.21722
- Cleveland Clinic. Vena Cava Filters: Purpose & Placement. 2025. Available from: https://my.clevelandclinic.org/health/treatments/17609-vena-cava-filters
- Bilal H, et al. Complications of Inferior Vena Caval Filters. NIH. 1997. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3036364/
- Alpaslan M, et al. Embolic Protection Devices in Transcatheter Aortic Valve Implantation. NIH. 2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12194329/
- Almanza DC, et al. Comparative Review of Large Animal Models for Suitability of Cardiovascular Devices. IJMS. 2024. Available from: https://ijms.info/IJMS/article/view/763/1645
- Mohammadi H, et al. Simulation of blood flow in the abdominal aorta considering hyperelasticity of the wall. J Carme. 2021. Available from: https://jcarme.sru.ac.ir/article_1223.html
- Ketha S, et al. Comparative Review of Large Animal Models for Suitability of Cardiovascular Devices. IJMS. 2019. Available from: https://ijms.info/IJMS/article/download/763/1644?inline=1
A shared “Judicial & Medical” quote
Posted in Uncategorized, tagged humanity in medicine, medcial ethics, science and medicine on December 24, 2025|
Pro-coagulant state: Arterial vs venous thrombus risk , what are the differences ?
Posted in Uncategorized on December 21, 2025|
It would be silly to remind, it’s the same five liters of blood, that circulates across, both the arterial and venous system. But, its journey one away from the heart, and the other towards the heart are strikingly different. They are subjected to various hemodynamic forces, travels different terrains, at different speeds, thousands of kilometers of microvasculature along the cardiovascular highway, yet merging with each other every 15 seconds or so, at the pulmonary junction box. Have a look at the following images, to understand the distribution of the blood volume.
The first image is taken from the maverick physiologist Dr. Guyton’s textbook of physiology, and the second one from the equally famous Dr. Ganong’s. Both images depict the distribution of blood volume, the corresponding pressures, and velocity. Every cardiology fellow should recall these two images even in their sleep. Also mind, they circulate around the body, lifelong without clotting or bleeding, assisted by the right balance of pro and antithrombotic forces.
Why some of patient’s blood is more likely to get frozen ?
Logic would suggest venous thrombosis should be more prevalent than arterial thrombosis at any point of time and location. This is due to the slowness of the circulation and the enormous volume within the venous reservoir. But is this the clinical reality? It is indeed true, that incidence of minor venous thrombosis exceeds arterial thrombosis. Since venous thrombosis often gets lysed or get stuck in the lungs, it’s frequently under-recognized. Arterial thrombosis causes more damage in an important sense, as it leads to target organ ischemia.
Apart from hemodynamic factors, the 200 year old Virchow’s triad is very much alive. The vessel wall integrity, intrinsic defects in the coagulation and anticoagulant/fibrinolytic molecules, the genetic susceptibility are the important determining factors. The RBC and platelet behaviour too changes, in high and low pressure environments.
How to diagnose a patient who is in a procoagulant state?
The topic is so complex .Many things are still poorly understood. We should have a checklist of all systemic conditions that can cause increased risk of thrombus. We know pregnancy is inherently a procoagulant state, as is manifest or concealed malignancy.
What we normally do ?
It is very easy to tick the coagulation profile/panel slip and pass it on to the nursing staff. Some of us take another easy route, referring such patients to a rheumatologist for the risk-stratifying job. This is probably because we strongly believe SLE and connective tissue disorders are the first culprits.
I think we need to engage the hematologist more often because thrombosis is not only due to excess coagulation. It is also due to a lack of enough circulating anticoagulants. (As a cardiologist, sometimes I feel awkward. to call myself an expert of the circulatory system, with almost zero knowledge of how the blood clots or dissolves.) This article tries to differentiate the risk factors operative on the venous and arterial sides. It is only a gross attempt; many risk factors are invisible and are common between arterial and venous thrombus.
For a detailed analysis of Sydney criteria /ACR-EULAR (Reference 7 )
How to treat pro-coagulant state?
Fortunately, identifying the thrombosis prone patients is complex , but the treatment is fairly simple. We have only few options: Aspirin, Warfarin, and NOACs *We need to choose one of them. The general rule is aspirin doesn’t work much on the venous side. I don’t know how far this is really true. (It has something to do with the shearing force of platelets? ) However, in obstetrics, the placental circulation is full of low pressure venous plexus where Aspirin is used as a norm.
Between Warfarin and NOACs, there is absolutely no doubt Warfarin is the clear winner on the arterial side. Because of monitoring issues and fear of bleeding, we are compelled to switch to NOACs in many situations. Beware, think twice before prescribing NOAC for prophylaxis against arterial thrombus. The venous side does not have much difference in choice. *Heparin (& its glamor sibling LMWH) is a unique molecule, which has ability to work on both arterial and venous sides.
References
Postamble
The article doesn’t discuss the intra vascular metals, wires, devices, valves, pacemakers , related thrombosis. Here there is a known trigger. It is possible, they also influenced by the baseline factors of pro-coagulation discussed above.
Categories
-
-
The contents of the this blog is being published as Kindle E book , as per the request of many of the readers. Every article will continue to be open source in this site. Again I shall reiterate the book format is not aimed at any commercial intent. It is only to facilitate learning in a single book format Here is the link to book
https://amzn.in/d/euhL5vu Archives
- April 2026 (2)
- March 2026 (9)
- February 2026 (8)
- January 2026 (8)
- December 2025 (11)
- November 2025 (7)
- October 2025 (8)
- September 2025 (7)
- August 2025 (9)
- July 2025 (10)
- June 2025 (8)
- May 2025 (9)
- April 2025 (7)
- March 2025 (10)
- February 2025 (4)
- January 2025 (9)
- December 2024 (11)
- November 2024 (8)
- October 2024 (10)
- September 2024 (5)
- August 2024 (5)
- July 2024 (6)
- June 2024 (5)
- May 2024 (4)
- April 2024 (7)
- March 2024 (4)
- February 2024 (8)
- January 2024 (6)
- December 2023 (8)
- November 2023 (13)
- October 2023 (14)
- September 2023 (5)
- August 2023 (6)
- July 2023 (10)
- June 2023 (5)
- May 2023 (5)
- April 2023 (4)
- March 2023 (5)
- February 2023 (2)
- January 2023 (7)
- December 2022 (3)
- November 2022 (5)
- October 2022 (5)
- September 2022 (4)
- August 2022 (3)
- July 2022 (9)
- June 2022 (2)
- May 2022 (1)
- April 2022 (2)
- March 2022 (1)
- February 2022 (3)
- January 2022 (7)
- December 2021 (3)
- November 2021 (5)
- October 2021 (8)
- September 2021 (4)
- August 2021 (6)
- July 2021 (6)
- June 2021 (7)
- May 2021 (5)
- April 2021 (4)
- March 2021 (3)
- February 2021 (6)
- January 2021 (8)
- December 2020 (4)
- November 2020 (5)
- October 2020 (7)
- September 2020 (7)
- August 2020 (10)
- July 2020 (6)
- June 2020 (9)
- May 2020 (9)
- April 2020 (5)
- March 2020 (7)
- February 2020 (3)
- January 2020 (4)
- December 2019 (4)
- November 2019 (6)
- October 2019 (3)
- September 2019 (6)
- August 2019 (3)
- July 2019 (1)
- June 2019 (3)
- May 2019 (2)
- April 2019 (2)
- March 2019 (2)
- February 2019 (4)
- January 2019 (2)
- December 2018 (2)
- November 2018 (2)
- October 2018 (2)
- September 2018 (1)
- August 2018 (2)
- July 2018 (3)
- June 2018 (1)
- May 2018 (3)
- April 2018 (1)
- March 2018 (3)
- February 2018 (3)
- January 2018 (1)
- December 2017 (3)
- November 2017 (3)
- October 2017 (3)
- September 2017 (2)
- August 2017 (2)
- July 2017 (2)
- June 2017 (2)
- May 2017 (4)
- April 2017 (3)
- March 2017 (3)
- February 2017 (5)
- January 2017 (3)
- December 2016 (2)
- November 2016 (5)
- October 2016 (4)
- September 2016 (3)
- August 2016 (5)
- July 2016 (3)
- June 2016 (4)
- May 2016 (3)
- April 2016 (6)
- March 2016 (4)
- February 2016 (3)
- January 2016 (5)
- December 2015 (6)
- November 2015 (5)
- October 2015 (8)
- September 2015 (2)
- August 2015 (5)
- July 2015 (7)
- June 2015 (4)
- May 2015 (6)
- April 2015 (5)
- March 2015 (7)
- February 2015 (15)
- January 2015 (8)
- December 2014 (5)
- November 2014 (9)
- October 2014 (7)
- September 2014 (9)
- August 2014 (5)
- July 2014 (11)
- June 2014 (5)
- May 2014 (4)
- April 2014 (5)
- March 2014 (8)
- February 2014 (8)
- January 2014 (5)
- December 2013 (7)
- November 2013 (7)
- October 2013 (14)
- September 2013 (12)
- August 2013 (15)
- July 2013 (15)
- June 2013 (15)
- May 2013 (15)
- April 2013 (15)
- March 2013 (15)
- February 2013 (15)
- January 2013 (15)
- December 2012 (15)
- November 2012 (15)
- October 2012 (15)
- September 2012 (15)
- August 2012 (15)
- July 2012 (15)
- June 2012 (15)
- May 2012 (15)
- April 2012 (15)
- March 2012 (15)
- February 2012 (15)
- January 2012 (15)
- December 2011 (15)
- November 2011 (17)
- October 2011 (17)
- September 2011 (17)
- August 2011 (21)
- July 2011 (20)
- June 2011 (17)
- May 2011 (15)
- April 2011 (17)
- March 2011 (25)
- February 2011 (20)
- January 2011 (20)
- December 2010 (18)
- November 2010 (21)
- October 2010 (21)
- September 2010 (25)
- August 2010 (20)
- July 2010 (10)
- June 2010 (11)
- May 2010 (19)
- April 2010 (16)
- March 2010 (14)
- February 2010 (22)
- January 2010 (18)
- December 2009 (20)
- November 2009 (20)
- October 2009 (3)
- September 2009 (21)
- August 2009 (19)
- July 2009 (12)
- June 2009 (12)
- May 2009 (11)
- April 2009 (15)
- March 2009 (21)
- February 2009 (4)
- January 2009 (12)
- December 2008 (13)
- November 2008 (9)
- October 2008 (22)
- September 2008 (20)
- August 2008 (16)
- July 2008 (14)
- June 2008 (7)
Blog Stats
- 6,643,989 hits
Please give your feed back .
Click below to see who is watching this website live !
- This site will never aim for profit. Still ,this donation link is added at the request of few visitors who wanted to contribute and of-course that will help make it sustainable .
Please Note
Dr.S.Venkatesan MD 
